ODYY Odyssey Health, Inc.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1626644 · Fiscal year ends 07/31
Financial factors as of 2026-07-31 (2026Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-228.8%
TTM EPS YoY-150.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-5,799.8%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets8,303.6%
Debt / equity—
Current ratio0.01x
Interest coverage-0.58x
Cash quality & payout
Operating cash flow / net income0.18x
Accruals ratio-4,740.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q4*2026-07-31 | 2026Q32026-04-30 | 2026Q22026-01-31 | 2026Q12025-10-31 | 2025Q4*2025-07-31 | 2025Q32025-04-30 | 2025Q22025-01-31 | 2025Q12024-10-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | — | — | — | — | $0 | $0 | $0 | $0 |
| SG&A expense | $130,307 | $297,554 | $181,942 | $303,190 | $264,077 | $129,055 | $156,593 | $579,427 |
| Operating income | -$130,307 | -$297,554 | -$181,942 | -$303,190 | -$155,678 | -$129,055 | -$156,593 | -$579,427 |
| Interest expense | $547,500 | $527,551 | $412,429 | $95,336 | $58,905 | $61,395 | $63,431 | $68,781 |
| Net income | -$2.41M | $765,890 | -$3.60M | -$483,447 | -$251,916 | -$251,743 | -$220,126 | -$1.02M |
| EBITDA | — | — | — | — | — | -$129,055 | -$156,593 | -$579,427 |
| EPS (basic) | — | 0.01 | -0.03 | 0.00 | — | 0.00 | 0.00 | -0.01 |
| EPS (diluted) | — | 0.01 | -0.03 | 0.00 | — | 0.00 | 0.00 | -0.01 |
| Weighted avg. shares (diluted) | — | 186.67M | 107.85M | 106.04M | — | 104.71M | 104.71M | 104.71M |
| Balance sheet | ||||||||
| Cash & equivalents | $122,361 | $297,806 | $616,327 | $25,586 | $19,084 | $3,186 | $7,187 | $53,865 |
| Current assets | $147,859 | $373,779 | $721,304 | $143,622 | $49,723 | $67,359 | $108,361 | $182,540 |
| Total assets | $147,859 | $373,779 | $721,304 | $143,622 | $49,723 | $164,508 | $266,866 | $341,045 |
| Current liabilities | $12.28M | $10.12M | $11.32M | $7.30M | $7.00M | $6.87M | $6.73M | $6.62M |
| Total liabilities | $12.28M | $10.12M | $11.32M | $7.30M | $7.00M | -$6.54M | $6.73M | $6.62M |
| Shareholders' equity | -$12.13M | -$9.75M | -$10.60M | -$7.16M | -$6.95M | $6.70M | -$6.46M | -$6.28M |
| Shares outstanding | 105.97M | 100.97M | 99.85M | 99.85M | 96.71M | 96.71M | 96.71M | 96.71M |
| Cash flow statement | ||||||||
| Operating cash flow | -$159,580 | -$318,521 | -$284,259 | -$283,998 | -$48,199 | -$4,001 | -$46,678 | -$248,514 |
| Investing cash flow | — | — | — | — | $69,787 | $0 | — | — |
| Financing cash flow | -$15,865 | $0 | $875,000 | $290,500 | -$5,690 | $0 | $0 | $300,000 |
| Depreciation & amortization | — | — | — | — | — | $0 | $0 | $0 |
| Stock-based compensation | $5,408 | $0 | $0 | $0 | $0 | $11,781 | $36,131 | $60,487 |
Free plan shows the latest 8 periods; Pro shows all 48 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.